Details of the Drug Combinations

General Information of This Drug (ID: DMHPD2Y)

• Drug Name: SODIUM CITRATE (DMHPD2Y)
• Synonyms: Sodium citrate; 68-04-2; TRISODIUM CITRATE; Citrosodine; Sodium citrate anhydrous; Citrosodina; Natrocitral; Citrosodna; Citreme; Citnatin; sodium citrate, anhydrous; Sodium 2-hydroxypropane-1,2,3-tricarboxylate; Trisodium citrate anhydrous; Citric acid, trisodium salt; Trisodium citrate, anhydrous; Citric acid trisodium salt; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt; UNII-RS7A450LGA; FEMA No. 3026; CCRIS 3293; Sodium citrate (Na3C6H5O7); HSDB 5201; EINECS 200-675-3; RS7A450LGA; CHEBI:53258; Trisodium 2-hydroxy-1

Indication

Common cold; ICD 11: CA00; Status: Approved [1]; Cough; ICD 11: MD12; Status: Approved [1]; Peptic ulcer; ICD 11: DA61; Status: Approved [1]; Rhinitis; ICD 11: FA20; Status: Approved [1]; Discovery agent; ICD 11: N.A.; Status: Investigative [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Pravastatin + SODIUM CITRATE	DCJIS89	Pravastatin	Autosomal Dominant Polycystic Kidney Disease	[3]

References

• [1] SODIUM CITRATE FDA Label
• [2] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [3] ClinicalTrials.gov (NCT04284657) Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease